PrimeCell to participate at the World Stem Cells Congress
PrimeCell is pleased to announce its participation at The 2012 World Stem Cells and Regenerative Medicine Congress, the region´s largest conference within the industry, which is scheduled to take place on May 21 – 23, 2012 in London, UK, at Victoria Park Plaza.
PrimeCell extends its technology portfolio
PrimeCell, emerging regenerative medicine firm in the Czech Republic, is pleased to announce that TAP Biosystems, a leading supplier of innovative cell culture systems and consumables for life science applications is installing a system, namely, CellBase CT™ to improve reproducibility and affordability of its autologous cell therapies.
German research companies set sights on the Czech Republic
According to Germany Trade and Invest the Czech Republic is increasingly becoming and an attractive market within the research and development industry, which enhances investment opportunities for German companies.
NTC in the Millennium show
Mr. Michal Zahradníček, the chair of the NTC supervisory board, was a guest of Monday’s Millenium TV magazine.
NTC under the auspices of Brno
The city of Brno, represented by its chief magistrate Roman Onderka, has taken over the sponsorship for the National Tissue Center projects. The projects are mostly related to the research of new types of materials and experimental development of modern therapy devices.
The grand opening of the National Tissue Center in Brno Bohunice is scheduled for 15th September 2011. Guests will have the option of examining the super-clean areas of the NTC production laboratories. The Minister of Health of the Czech Republic, doc. MUDr. Leoš Heger, CSc., will also be present at the grand opening.
The United States government won a Federal Court lawsuit in the battle for stem cells
Obama’s government won a lawsuit at the Federal Court on 27th June 2011 regarding the temporary suspension of embryonic stem cell research. The federal judge has rejected the action proposed by two scientists who were trying to stop the financing of research on human embryos by the federal government. The decision is a victory for the advocates of controlled and government-financed modern research of human diseases. The area of embryonic stem cell research is highly controversial, as in most cases the embryo dies within 4-5 days after stem cells are withdrawn.
Press conference for the introduction of the National Tissue Center, a.s. (NTC)
The press conference took place on Thursday 25th August in Prague. MUDr. Roman Kraus, the director of University Hospital Brno, MUDr. Barbara Kubešová, the head physician and director of NTC, Prof. MUDr. Pavel Brychta, CSc., the head of the Burn and Reconstruction Surgery Clinic at University Hospital Brno, MUDr. Pavel Březovský, MBA, director of the Transplantation Coordination Center for the Czech Republic and RNDr. Eva Matějková, the head of the Cellular Therapy Department and qualified specialist for the production of medications at NTC, have introduced the newly constructed research, development and production facilities of the National Tissue Center. The new modern laboratories at NTC comply with all strict legislative requirements and all the criteria on the level of cleanness, and will host the development and production of preparations used in modern therapy, cellular therapy and of tissue transplants.
Chondros s.r.o. receive a trademark
Our subsidiary Chondros s.r.o. has received a trademark. The registration of the trademark is a continuation of the company's unique business strategy. The trademark registration is available for download here.
First medication from stem cells approved for clinical use in South Korea
After six years of extensive clinical studies, the South Korean Food and Drug Administration has approved stem cells for clinical use. South Korea is the first country in the world to allow treatment of patients by stem cells. Development biotechnology companies have developed and clinically tested a medication obtained via cultivation from stem cells of the bone marrow. The preparation is designated for treating patients with acute coronary syndrome, and is applied intravenously to patients after an acute cardiac event. The producer claims that a single injection improves heart operation by 6% within six months. Further clinical studies and efficiency testing are planned.
Transplantology helps new life
We can expect further developments in transplantology following the recent successful facial transplant realized by Czech doctor MUDr. Bohdan Pomahač in the United States and many other extraordinary surgical operations in the Czech Republic and abroad. Transplants can be used, based on the type of wound or disease, to save lives, improve quality of living or significantly extend one's life. It can also be a very important tool in helping the creation of new life, as we have just found out.
A woman with a transplanted heart has given birth last week to a healthy girl in the maternity hospital U Apolináře. This is the first such event in the Czech Republic. The news was given by the head of the cardiocenter of Prague’s Institute for Clinical and Experimental Medicine, prof. Jan Pirk, who performed the transplant 2.5 years ago.
Amendment of health insurance law presents a new opportunity for the treatment of patients with medical preparations of the National Tissue Center
On 21st June 2011 the Chamber of Deputies of the Czech Republic has approved a novelization of the law on public health insurance no. 48/1997.